Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse

In acute myeloid leukemia (AML), the assessment of post‐treatment minimal residual disease (MRD) may inform a more effective management approach. We investigated the prognostic utility of next‐generation sequencing (NGS)‐based MRD detection undertaken before hematopoietic stem cell transplantation (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology Jg. 94; H. 8; S. 902 - 912
Hauptverfasser:	Press, Richard D., Eickelberg, Garrett, Froman, Allison, Yang, Fei, Stentz, Alex, Flatley, Ellen M., Fan, Guang, Lim, Jeong Y., Meyers, Gabrielle, Maziarz, Richard T., Cook, Rachel J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Hoboken, USA John Wiley & Sons, Inc 01.08.2019 Wiley Subscription Services, Inc
Schlagworte:	Acute myeloid leukemia Adult Aged Cohort Studies Female Flow cytometry Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells High-Throughput Nucleotide Sequencing - methods Humans Leukemia Leukemia, Myeloid, Acute - epidemiology Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Male Middle Aged Minimal residual disease Mutation Myeloid leukemia Neoplasm, Residual - epidemiology Neoplasm, Residual - genetics Neoplasm, Residual - therapy p53 Protein Recurrence Retrospective Studies Stem cell transplantation Stem cells Transplantation Conditioning - methods Transplants & implants
ISSN:	0361-8609, 1096-8652, 1096-8652
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!